subjects entered into the trial may go thru a 0-4 weeks screening (Screening Phase). On the Intervention phase, subjects will be followed for 7 days which includes: entry criteria assessments and settling at the inpatient unit on Day 0, a single-dose I.V. infusion with data collection on Day 1 followed by 24 hours monitoring (Day 2), a 7-day and 28-day outpatient follow-up visit (Follow-Up Phase).

Cardiovascular Disease

subject will receive a slow I.V. infusion of the Fx-5A peptide complex. Five to 10 mL of blood will be collected at 30min (+/- 5min), 1h (+/-10min), 2h (+/-10min), 4h (+/-15min), 8h (+/-30min), 12h (+/-30min), and 24h (+/- 30min) for laboratory tests and to be stored for research tests (The goal will be to collect the samples at the exact time, but a delay within the +/- specified time will not be considered a deviation). The patient will be dismissed, as inpatient, 24-36 hours after the beginning of the treatment.

Fx-5A peptide complex

National Institutes of Health Clinical Center

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers

An Intravenous, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers

A 'complete study' is defined by the procedures described up to day 7 after Fx-5A infusion, the intervention phase of the study. A 28 days follow up is designed to study the immunogenicity of the drug. Once a subject completes the day 28 follow up the study is ended for the subject ('end of the study').

National Heart, Lung, and Blood Institute (NHLBI)

Participants will be randomized to consume 5% of total energy intake from medium chain triglycerides.

Participants will be randomized to consume 5% of total energy intake from long chain triglycerides.

Healthy

Medium chain triglycerides

Long chain triglycerides

University of Minnesota

MiCrobiome dieT Study

Effect of Normal Dietary Intake and Medium Chain Triglycerides Supplementation on the Human Microbiome

Collected as 24-hour daily recalls assessed using novel methods for dietary pattern assessment

colitis/triglyceride

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers

MiCrobiome dieT Study

Täydellisin lääketieteellinen tietokanta tieteen tukemana